GSA Capital Partners LLP Has $519,000 Holdings in Allakos Inc. (NASDAQ:ALLK)

GSA Capital Partners LLP increased its stake in Allakos Inc. (NASDAQ:ALLK) by 11.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 794,896 shares of the company’s stock after buying an additional 84,750 shares during the quarter. GSA Capital Partners LLP owned approximately 0.89% of Allakos worth $519,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Point72 DIFC Ltd acquired a new stake in shares of Allakos in the 2nd quarter valued at approximately $25,000. Cubist Systematic Strategies LLC bought a new stake in Allakos in the 2nd quarter valued at $55,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Allakos in the 2nd quarter valued at $112,000. BNP Paribas Financial Markets raised its stake in Allakos by 1,041.1% in the 1st quarter. BNP Paribas Financial Markets now owns 205,663 shares of the company’s stock valued at $259,000 after acquiring an additional 187,640 shares during the period. Finally, Acadian Asset Management LLC raised its stake in Allakos by 32.4% in the 2nd quarter. Acadian Asset Management LLC now owns 1,762,814 shares of the company’s stock valued at $1,761,000 after acquiring an additional 431,175 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

Allakos Trading Down 5.6 %

ALLK opened at $1.01 on Wednesday. Allakos Inc. has a 1-year low of $0.54 and a 1-year high of $3.41. The stock’s fifty day simple moving average is $0.89 and its 200 day simple moving average is $0.94. The stock has a market cap of $90.23 million, a PE ratio of -0.50 and a beta of 1.03.

Allakos (NASDAQ:ALLK) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. Equities analysts forecast that Allakos Inc. will post -1.16 earnings per share for the current year.

Analysts Set New Price Targets

Separately, JMP Securities restated a “market outperform” rating and issued a $3.00 price target on shares of Allakos in a research note on Thursday, September 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Allakos currently has a consensus rating of “Hold” and a consensus target price of $1.67.

Allakos Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.